Added to YB: 2026-03-16
Pitch date: 2026-03-13
MRNA [neutral]
Moderna, Inc.
Author Info
Legal Special Situations is keeping you up to date with current legal issues in the commercial sphere, breaking down investment opportunities and market effects. Sign up for the newsletter.
Company Info
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally.
Market Cap
$22.1B
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-5.56
P/E
-7.72
EV/Sales
7.86
Sector
Biotechnology
Category
special_situation
Moderna Just Paid Nearly a Billion Dollars for a Patent Licence - Here’s What To Pay Attention To
MRNA (quick overview): Settled Arbutus LNP patent suit for $950M guaranteed by July 2026 + contingent $1.3B if §1498 govt immunity appeal fails. Arbutus gets ~$190M guaranteed (~20% mkt cap), up to ~$450M total if appeal succeeds. Similar Pfizer/BioNTech suit pending.
Read full article (4 min)